scholarly journals Erratum to: Galectin-3 in Cardiac Remodeling and Heart Failure

2012 ◽  
Vol 9 (3) ◽  
pp. 163-163 ◽  
Author(s):  
Rudolf A. de Boer ◽  
Lili Yu ◽  
Dirk J. van Veldhuisen
Keyword(s):  
Heart Failure ◽  
Cardiac Remodeling ◽  
Galectin 3

scholarly journals The Role of Galectin-3 and ST2 in Cardiology: A Short Review

Biomolecules ◽  
2021 ◽  
Vol 11 (8) ◽  
pp. 1167
Author(s):  
Ana Merino-Merino ◽  
Jeronimo Gonzalez-Bernal ◽  
Dario Fernandez-Zoppino ◽  
Ruth Saez-Maleta ◽  
Jose-Angel Perez-Rivera
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Coronary Heart Disease ◽  
Cardiac Remodeling ◽  
Short Review ◽  
Cardiac Diseases ◽  
Myocardial Cells ◽  
Prognostic Role ◽  
Galectin 3

Galectin-3 is a lectin that binds beta-galactosides. It is involved in cardiac remodeling and fibrosis through the activation of macrophages and fibroblasts. ST2 is secreted by myocardial cells due to cardiac overload. These two biomarkers have been traditionally studied in the field of heart failure to guide medical therapy and detect the progression of the disease. Nevertheless, there are novel evidences that connect galectin-3 and ST2 with coronary heart disease and, specifically, with atrial fibrillation. The aim of this article is to concisely review the diagnostic and prognostic role of galectin-3 and ST2 in different cardiac diseases.

Galectin-3 as a marker for clinical prognosis and cardiac remodeling in acute heart failure

Herz ◽  
2017 ◽  
Vol 43 (2) ◽  
pp. 146-155 ◽  
Author(s):  
R. I. Lala ◽  
D. Lungeanu ◽  
D. Darabantiu ◽  
L. Pilat ◽  
M. Puschita
Keyword(s):  
Heart Failure ◽  
Acute Heart Failure ◽  
Cardiac Remodeling ◽  
Clinical Prognosis ◽  
Galectin 3

scholarly journals Galectin-3 in Cardiac Remodeling and Heart Failure

2010 ◽  
Vol 7 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Rudolf A. de Boer ◽  
Lili Yu ◽  
Dirk J. van Veldhuisen
Keyword(s):  
Heart Failure ◽  
Cardiac Remodeling ◽  
Galectin 3

Protective role of peroxiredoxin-4 in heart failure

2020 ◽  
Vol 134 (1) ◽  
pp. 71-72
Author(s):  
Naseer Ahmed ◽  
Masooma Naseem ◽  
Javeria Farooq
Keyword(s):  
Heart Failure ◽  
Cardiac Fibroblasts ◽  
Protective Role ◽  
Oxidative Stress Markers ◽  
Stress Markers ◽  
Total Antioxidant ◽  
Galectin 3 ◽  
Consequent Increase ◽  
And Oxidative Stress

Abstract Recently, we have read with great interest the article published by Ibarrola et al. (Clin. Sci. (Lond.) (2018) 132, 1471–1485), which used proteomics and immunodetection methods to show that Galectin-3 (Gal-3) down-regulated the antioxidant peroxiredoxin-4 (Prx-4) in cardiac fibroblasts. Authors concluded that ‘antioxidant activity of Prx-4 had been identified as a protein down-regulated by Gal-3. Moreover, Gal-3 induced a decrease in total antioxidant capacity which resulted in a consequent increase in peroxide levels and oxidative stress markers in cardiac fibroblasts.’ We would like to point out some results stated in the article that need further investigation and more detailed discussion to clarify certain factors involved in the protective role of Prx-4 in heart failure.

Hostile attribution is associated with increased galectin-3 in heart failure patients

2013 ◽  
Author(s):  
Wawrzyniak Andrew J. ◽  
Kerry S. Whittaker ◽  
Sarah M. Godoy ◽  
Kristie M. Harris ◽  
Maria N. Banis ◽  
...  
Keyword(s):  
Heart Failure ◽  
Hostile Attribution ◽  
Heart Failure Patients ◽  
Galectin 3

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

A PILOT STUDY: PLASMA GALECTIN-3 LEVEL IN HEART FAILURE PATIENTS

2017 ◽  
pp. 101-106
Author(s):  
Thi Thanh Hien Bui ◽  
Hieu Nhan Dinh ◽  
Anh Tien Hoang
Keyword(s):  
Heart Failure ◽  
Chronic Kidney Disease ◽  
Acute Coronary Syndrome ◽  
Kidney Disease ◽  
Heart Failure Patients ◽  
Coronary Syndrome ◽  
Nyha Classification ◽  
Galectin 3 ◽  
Severe Chronic Kidney Disease ◽  
Esc Guidelines

Background: Despite of considerable advances in its diagnosis and management, heart failure remains an unsettled problem and life threatening. Heart failure with a growing prevalence represents a burden to healthcare system, responsible for deterioration of patient’s daily activities. Galectin-3 is a new cardiac biomarker in prognosis for heart failure. Serum galectin-3 has some relation to heart failure NYHA classification, acute coronary syndrome and clinical outcome. Level of serum galectin-3 give information for prognosis and help risk stratifications in patient with heart failure, so intensive therapeutics can be approached to patients with high risk. Objective: To examine plasma galectin-3 level in hospitalized heart failure patients, investigate the relationship between galectin-3 level with associated diseases, clinical conditions and disease progression in hospital. Methodology: Cross sectional study. Result: 20 patients with severe heart failure as NYHA classification were diagnosed by The ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (2012) and performed blood test for serum galectin-3 level. Increasing of serum galectin-3 level have seen in all patients, mean value is 36.5 (13.7 – 74.0), especially high level in patient with acute coronary syndrome and patients with severe chronic kidney disease. There are five patients dead. Conclusion: Serum galectin-3 level increase in patients with heart failure and has some relation to NYHA classification, acute coronary syndrome. However, level of serum galectin-3 can be affected by severe chronic kidney disease, more research is needed on this aspect Key words: Serum galectin-3, heart failure, ESC Guidelines, NYHA

Sign in / Sign up

Export Citation Format

Share Document